60 filings
8-K
Dermira, Inc.
20 Feb 20
Completion of Acquisition or Disposition of Assets
9:30am
8-K
Dermira, Inc.
10 Jan 20
Entry into a Material Definitive Agreement
6:40am
8-K
Dermira, Inc.
13 Nov 19
Dermira Elects Halley E. Gilbert to its Board of Directors
4:20pm
8-K
Dermira, Inc.
5 Nov 19
Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update
4:12pm
8-K
Dermira, Inc.
9 Oct 19
Other Events
9:12am
8-K
j25bq
7 Aug 19
Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update
4:13pm
8-K
cnpau0q45tlupuc
25 Jun 19
Other Events
6:06am
8-K
sagm8 by8
10 Jun 19
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
6byvisvv7g
7 May 19
Dermira Reports First Quarter 2019 Financial Results
4:10pm
8-K
v3o 24s9sz
20 Mar 19
Dermira Prices $130.0 Million Public Offering of Common Stock
4:05pm
8-K
gor6op9spsahan4igf
18 Mar 19
Other Events
4:04pm
8-K
kjk 949oae
18 Mar 19
Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
7:12am
8-K
lgzm fjaset835ahd
28 Feb 19
Entry into a Material Definitive Agreement
8:07am
8-K
2qh65ix
26 Feb 19
Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
4:09pm
8-K
qs3kv
12 Feb 19
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
12:00am
8-K
jyaqfrimfmxf4o
7 Jan 19
Other Events
6:08am
8-K
e6egjb70g 0fxawk
4 Dec 18
Entry into a Material Definitive Agreement
7:45am
8-K
ddoz59oh3 rd
7 Nov 18
Dermira Reports Third Quarter 2018 Financial Results
4:14pm
8-K
y5qete96x777dgb ii
1 Oct 18
Regulation FD Disclosure
4:01pm
8-K
kymli5siywg5uew
5 Sep 18
Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis
12:00am